{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-027854","form_type":"8-K","ticker":"DYAI","cik":"0001213809","company_name":"DYADIC INTERNATIONAL INC","filed_at":"2023-10-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.447385+00:00","generated_at":"2026-06-10T03:15:04.145766+00:00","sec_items":["1.02"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Dyadic's collaboration with Janssen terminated; wind-down by Dec 31, 2023","bullets":["Janssen Biotech provided written notice on Oct 2, 2023 to terminate the Research, License, and Collaboration Agreement with Dyadic.","Collaboration effective end date is December 31, 2023.","Agreement originally entered Dec 16, 2021 for manufacture of therapeutic proteins using Dyadic's C1 platform."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-027854","json":"https://secwatch.observer/filing/0001437749-23-027854.json","markdown":"https://secwatch.observer/filing/0001437749-23-027854.md","text":"https://secwatch.observer/filing/0001437749-23-027854.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1213809/000143774923027854/0001437749-23-027854-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1213809/000143774923027854/dyai20231004c_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T03:15:04.145766+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"12815493ab9a29922f4c9537bd9b40e49129710a","claim":"DYADIC INTERNATIONAL INC terminated Research, License, and Collaboration Agreement with Janssen Biotech, Inc. (effective 2023-12-31).","evidence_excerpt":"Pursuant to Section 12.3 of the Agreement, on October 2, 2023, Janssen provided written notice to Dyadic that it has decided to wind down the collaboration with an effective end date of December 31, 2023.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1213809/000143774923027854/0001437749-23-027854-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Janssen Biotech, Inc."},{"label":"Effective","value":"2023-12-31"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}